Enda Kenny (Mayo, Fine Gael) | Oireachtas source

He has pointed out that the National Centre for Pharmacoeconomics, NCPE, which undertook an assessment of Orkambi, noted from a clinical point of view that the drug was not considered cost-effective in terms of quality of life for the people involved at almost €160,000 per patient per year, as submitted by Vertex. The NCPE estimated the cost-effective price at €30,000. There is a big difference between €30,000 and €160,000. It is in there that realism needs to-----

See this speech in context